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Abstract
Aim This article gives an overview on the current status of
hypofractionated radiotherapy in the treatment of prostate
cancer with a special focus on the applicability in routine
use.
Methods Based on a recently published systematic review
the German Society of Radiation Oncology (DEGRO) ex-
pert panel added additional information that has become
available since then and assessed the validity of the infor-
mation on outcome parameters especially with respect to
long-term toxicity and long-term disease control.
Results Several large-scale trials on moderate hypofrac-
tionation with single doses from 2.4–3.4 Gy have recently
finished recruiting or have published first results sugges-
tive of equivalent outcomes although there might be a trend
for increased short-term and possibly even long-term tox-
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icity. Large phase 3 trials on extreme hypofractionation
with single doses above 4.0 Gy are lacking and only very
few prospective trials have follow-up periods covering more
than just 2–3 years.
Conclusion Until the results on long-term follow-up of sev-
eral well-designed phase 3 trials become available, moder-
ate hypofractionation should not be used in routine prac-
tice without special precautions and without adherence to
the highest quality standards and evidence-based dose frac-
tionation regimens. Extreme hypofractionation should be
restricted to prospective clinical trials.
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Hypofraktionierte Radiotherapie des lokalisierten
Prostatakarzinoms
Zusammenfassung
Ziel Diese Übersichtsarbeit soll den aktuellen Status der hy-
pofraktionierten Radiotherapie des Prostatakarzinoms mit
dem Fokus auf die Anwendung in der Routinetherapie dar-
stellen.
Methoden Basierend auf einem kürzlich erschienen syste-
matischen Review zur Hypofraktionierung sind durch das
DEGRO Expertengremium zusätzliche, in der Zwischen-
zeit verfügbar gewordene Informationen mit berücksichtigt
worden. Die Validität der Aussagen zu Ergebnissen wurde
speziell im Hinblick auf die Langzeittoxizität und -erkran-
kungskontrolle bewertet.
Ergebnisse Mehrere große Phase-3-Studien zur moderaten
Hypofraktionierung mit Dosen von 2,4–3,4 Gy pro Fraktion
haben die Rekrutierung beendet oder bereits erste Resultate
berichtet, die auf eine Äquivalenz hindeuten, wenngleich es
einen Trend zu vermehrter akuter und möglicherweise auch
später Toxizität gibt. Große Phase-3-Studien zur extremen
Hypofraktionierung mit Einzeldosen von über 4,0 Gy gibt
es bisher nicht, und nur sehr wenige prospektive Studien
haben ein Follow-up von mehr als 2 bis 3 Jahren.
Schlussfolgerung Vor Veröffentlichung der Langzeitdaten
der existierenden, gut geplanten und durchgeführten pros-
pektiv-randomisierten Studien sollte eine moderate Hypo-
fraktionierung in der Routine nicht ohne besondere Vorsicht
und unter Einhaltung höchster Qualitätsstandards und Ver-
wendung evidenzbasierter Schemata für Dosis und Frak-
tionierung angewendet werden. Eine extreme Hypofraktio-
nierung sollte prospektiven klinischen Studien vorbehalten
bleiben.
Schlüsselwörter Hypofraktionierung · Prostatakarzinom ·
Strahlentherapie
Introduction
Prostate cancer is one of the predominant malignancies
in men throughout the western world. Radiotherapy and
prostatectomy are the main interventions applied in patients
with a life expectancy long enough to justify possible treat-
ment-related side effects and long-term sequelae. Generally,
there is a broad consensus that both modalities offer a sim-
ilar chance of a cure but due to the different profiles of side
effects and impact on functional domains, they have their
specific pros and cons; therefore, counselling of patients is
much more time-consuming compared to other malignant
diseases, where the superiority of a respective treatment
option is unquestioned. One of the major drawbacks of ex-
ternal beam radiotherapy is the long time span needed to
deliver a complete course of radiotherapy, usually amount-
ing up to 2 months.
Mainly driven by a shortage of treatment facilities and/or
long travelling distances in countries with healthcare sys-
tems providing fewer but larger therapeutic units, hypofrac-
tionation, i. e. shortening of overall treatment time by deliv-
ering larger doses per fraction up to a lower total dose, has
attracted growing interest. In treating women with breast
cancer, moderate hypofractionation (i. e. daily doses of ap-
proximately 2.7 Gy) is nowadays broadly accepted as an
alternative to standard fractionation [1–3]. Prostate cancer
as a relatively slowly growing malignancy shows a better
prognosis than many other tumors, necessitating very long
follow-up times to evaluate the safety profile of therapeutic
modifications in terms of disease control as well as side
effects; therefore, any adoption of new treatment concepts
has to be scrutinized to a high degree. Especially in the
last few years, a rapid increase in reports on hypofraction-
ated radiotherapy for prostate cancer has been noted, which
prompted the present overview, supplementing a recently
published systematic review [4] and including guidance for
daily practice.
Biology
Traditionally, external beam irradiation regimens have been
developed over several decades and the mode of applica-
tion, i. e. doses per fraction of 1.8–2.0 Gy given 5 times per
week up to total doses exceeding 70 Gy have been shown
to be safe, with severe side effects being very rare events.
Most cancers and normal tissues behave differently when
exposed to radiation. The linear-quadratic equation serves
as a biomathematical model commonly applied to describe
fractionation sensitivity of tissues and to calculate isoeffec-
tive doses for different doses per fraction. Tissue-specific
α/β values derived from this model can be estimated from
clinical and preclinical data. As almost every human or-
gan is composed of different tissue types, the α/β values
may be different for distinct endpoints evaluated within the
same organ, emphasizing the need for cautious interpreta-
tion when testing new fractionation schemes.
Retrospective data derived from different modes of ra-
diotherapy application and fractionation initially suggested
very low α/β values for prostate cancer in the range of
1.5 Gy, i. e. lower than the α/β values of the surrounding
dose-limiting normal tissues. These data led to the hypothe-
sis that hypofractionation improves the therapeutic ratio for
radiotherapy of prostate cancer. Based on this hypothesis
randomized trials were initiated. The controversial discus-
sion on fractionation sensitivity of prostate cancer is further
complicated by the existence of a time factor [5]. Prostate
cancer is often a slowly growing tumor which may predict
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a low α/β value (and hence a high fractionation sensitiv-
ity) and a negligible time factor (loss of effect by increase
in overall treatment time); however, a large retrospective
analysis on external beam radiotherapy for prostate cancer
comprising 4839 patients demonstrated a significant and
clinically relevant time factor of 0.24 Gy/day with a 95 %
confidence interval of 0.03–0.44 Gy/day [6]. Of note, the
effect of androgen deprivation on the time factor is un-
known. Although the time factor for prostate cancer is not
as pronounced as in other tumor types, it has important im-
plications not only for trial design but also for clinical prac-
tice. As often with hypofractionation, the overall treatment
time is shorter than for conventional fractionation, thus the
suspected superiority of hypofractionation might not only
be explained by fractionation sensitivity or in other words
the α/β value for prostate cancer might be higher than ini-
tially suspected [7]. This is of high relevance for the design
of biologically driven fractionation schedules. The lack of
superiority of hypofractionation observed in the Fox Chase
trial [8, 18] does not support the assumption of a very low
α/β value for prostate cancer but suggests that the fraction-
ation sensitivities of prostate cancer and the dose-limiting
surrounding normal tissues overlap.
Given the contradictory and lacking evidence the Ger-
man Society of Radiation Oncology (DEGRO) expert panel
drew the following conclusions:
● The assumption of an α/β value for prostate cancer of
as low as 1.5 Gy might lead to an overestimation of the
effects of hypofractionation.
● Fractionation sensitivity of prostate cancer and surround-
ing tissues does not decisively differ; therefore, hypofrac-
tionated and accelerated study designs with a reduced to-
tal dose seem promising and may be possible without any
deterioration of the therapeutic ratio.
● The time factor may contribute in part to the efficacy of
hypofractionation.
● Due to the described uncertainties in assuming fraction-
ation sensitivities and the steep dose-response effects for
tumor control and for normal tissue toxicity, fractionation
concepts have to be tested in well-designed randomized
trials, such as the CHHiP, HYPRO and the RTOG 0415
studies and should not be mathematically derived.
● Only evidence-based fractionation schedules should be
used outside of clinical trials.
● Treatment interruptions leading to prolonged overall
treatment times can have negative consequences and
have to be adequately compensated.
Technology
The technological basis for external beam radiotherapy
has continuously developed over the last 2 decades and
a modern standard is now broadly available. A highly con-
formal radiotherapy, e. g. intensity modulated radiotherapy
(IMRT), with daily verification of the prostate position by
image-guided radiation therapy (IGRT) is the prerequisite
for all hypofractionation concepts. The target volume con-
cept in radiation therapy of prostate cancer forms the basis
for understanding the reduction in normal tissue compli-
cation probability (NTCP) by IGRT. Due to histological
multifocality of prostate cancer, the target of radiotherapy
is the entire prostate gland and also a subclinical infiltration
zone around the prostate needs to be considered carefully
to improve the probability of tumor control [9].
As radiation therapy is fractionated in clinical practice,
i. e. applied in small daily doses over several weeks a fur-
ther safety margin, the planning target volume (PTV) needs
to be defined around the clinical target volume (CTV). The
PTV includes possible positioning errors of the CTV by
potential inaccuracies in the daily set up, organ movement
from day to day (interfractional organ movement) and dur-
ing beam application (intrafractional organ movement). By
definition, this safety margin within the PTV around the
CTV contains only normal tissue. Another mandatory fac-
tor for hypofractionated radiotherapy of prostate cancer is
a daily verification of target volumes immediately before
irradiation. By visualizing the localization of the prostate,
the positioning error and the interfractional organ move-
ment can be widely corrected, thus reducing the PTV in the
ideal case without intra-fractional movement to the CTV.
Intrafractional movement can be minimized by fast beam
application, e. g. rotational IMRT and/or using high dose
rate flattening filter free (FFF) beam delivery. Institutional
IGRT protocols may specifically account for intrafractional
corrections [10]. As a result of these technical develop-
ments, the volume of normal tissue receiving high doses
and thus the NTCP might be reduced. In the clinical routine,
several IGRT methods have been established. Especially in
the case of prostate cancer, IGRT procedures should allow
3-dimensional imaging with soft tissue contrast or fiducial-
based techniques (intraprostatic markers) should be applied.
Moderate hypofractionation
Defining standard fractionation with single doses of
1.8–2.0 Gy is easier than defining the dose commonly
regarded as hypofractionation. For purposes of this review,
the arbitrary definition of moderate hypofractionation with
doses per fraction in the range of 2.2 up to 4.0 Gy and ex-
treme hypofractionation with a single dose beyond 4.0 Gy
has been chosen.
Data from eight randomized trials on moderate hypofrac-
tionation with appropriate sample size are available (table 1;
[8, 11–25]). Single doses ranging from 2.4 Gy to 3.4 Gy
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Table 1 Prospective randomized studies on moderate hypofractionated external beam radiotherapy for prostate cancer
Study n Median
FU
(months)
Risk groups/
Gleason
scores
Techniques Regimen (TD/fx/SD) Outcome Toxicity e = early,
otherwise: late tox
RTOG 0415
Lee et al. [11]
542
550
70 Low risk 3D-CRT/
IMRT
daily IGRT
73.8 Gy/41 fx/1.8 Gy
70 Gy/28 fx/
2.5 Gy
no ADT
5 years DFS
85.3 % (NS)
5 years DFS
86.3 %
G 2 GI 11.4 % (p =
0.05)
G 2 GU 20.5 % (p =
0.09)
G 2 GI 18.3 %
G 2 GU 26.2 %
Lukka et al. [12] 466
470
68 60 % GS 6
31 % GS 7
9 % GS 8–10
3DCRT
No IGRT
52.5 Gy/20 fx/2.63 Gy
66 Gy/33 fx/
2.0 Gy
no ADT
5 years
FFBF 47 %
(NS)
5 years
FFBF 42 %
G 3–4 GU + GI
3.2 %
(NS)
G 3–4 GU + GI
3.2 %
HYPRO
Aluwini et al.
[13, 14]
Incrocci et al.
[15]
397
407
60 27 % interme-
diate
73 % high
95 %
IMRT/
IGRT
78 Gy/39 fx/
2.0 Gy
64.6 Gy/19 fx/3.4 Gy
66 % ADT
5 years RFS
77.1 % (NS)
5 years RFS
80.5 %
3 years G2+ GU
39 %
3 years G3+
GU12.9 %
3 years G2+ GI
17.7 %
(3 years G3+ GU p =
0.02)
3 years G2+ GU
41.3 %
3 years G3+ GU
19.0 %
3 years G2+ GI
21.9 %
CHHiP
Dearnaley et al.
[16, 17]
1065/37 fx
1074/20 fx
1077/19 fx
62 15 % low
73 % interme-
diate
12 % high
IMRT
IGRT not
mandatory
74 Gy/37 fx/
2.0 Gy
60 Gy/20 fx/
3.0 Gy
57 Gy/19 fx/
3.0 Gy
97 % ADT
5 years PFS
(NS)
88.3 %
(37 fx)
vs.
90.6 %
(20 fx)
vs.
85.9 %
(19 fx)
Acute G2 + GI (p <
0.0001)
25 % (37 fx)
38 % (20 fx)
38 % (19 fx)
5 years G 2+ GI
(RTOG, NS)
13.7 % (37 fx)
11.9 % (20 fx)
11.3 % (19 fx)
5 years G 2 + GU
(RTOG, NS)
9.1 % (37 fx)
11.7 % (20 fx)
6.6 % (19 fx)
Fox Chase
Pollack et al. [8,
18]
Shaikh et al.
[19]abs
151
152
68 34 % GS 6
47 % GS 7
19 % GS 8–10
IMRT
daily
IGRT
70.2 Gy/26 fx/
2.7 Gy
76 Gy/38 fx/
2.0 Gy
46 % ADT
5 years
BCDF 23 %
(NS)
5 years
BCDF 21 %
5 years G 2+ GU
13 % (NS)
5 years G2+ GI 9 %
(NS)
5 years G2+ GU
22 %
5 years G2+ GI 9 %
incontinence worse at
3 years (p = 0.03) but
not at 5y
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Table 1 Prospective randomized studies on moderate hypofractionated external beam radiotherapy for prostate cancer (Continued)
Study n Median
FU
(months)
Risk groups/
Gleason
scores
Techniques Regimen (TD/fx/SD) Outcome Toxicity e = early,
otherwise: late tox
Yeoh et al. [20] 108
109
90 n. s. 2D/3DCRT
No IGRT
55 Gy/20 fx/
2.75 Gy
64 Gy/32 fx/
2.0 Gy
no ADT
7.5 years
FFBF 53 %
(p < 0.05)
7.5 years
FFBF 34 %
4 years GU; HR: 1.58
(95 % CI, 1.01–2.47)
favoring hypofrac-
tionation, but no
difference GI + GU
at 5 years FU
Kuban et al.
[21]abs/Hoffman
et al. [22]
102
101
60 28 % low
71 %
intermediate
1 % high
IMRT
IGRT
72 Gy/30 fx/
2.4 Gy
75.6 Gy/42 fx/
1.8 Gy
21 % ADT
5 years
FFBF 96 %
(NS)
5 years
FFBF 92 %
5 years G2+ GU
16 % (NS)
5 years G2+ GI 10 %
(NS)
5 years G2+ GU
17 %
5 years G2+ GI 5 %
Arcangeli et al.
[23–25]
83
85
70 26 % GS <7
74 % GS >7
3DCRT
No IGRT
62 Gy/20 fx/
3.1 Gy
80 Gy/40 fx/
2.0 Gy
100 % ADT
5 years
FFBF 85 %
(p = 0.065)
5 years
FFBF 74 %
3 years G 2+ GU
16 % (NS)
3 years G 2+ GI 17 %
(NS)
3 years G 2+ GU
11 %
3 years G 2+ GI 14 %
3DCRT three-dimensional conformal radiotherapy, abs data derived from abstract, ADT androgen deprivation therapy, BCDF biochemical
or clinical disease failure, CI confidence interval, DFS disease free survival, FFBF freedom from biochemical failure, FU follow-up,
fx fractions, GI gastrointestinal, G grade, GS Gleason score, GU genitourinary, HR hazard ratio, IGRT image-guided radiation therapy,
IMRT intensity-modulated radiation therapy, NS not significant, n. s. not stated, RFS relapse-free survival, ss statistically significant, SD single
dose, TD total dose
and total doses from 52.5 Gy to 72.0 Gy were applied in
the experimental arms. The largest study by far, the CHHiP
trial with more than 3200 patients included was first par-
tially published as a subset of 457 patients [17] and just
recently 5-year follow-up data became available [16]. Two
other large studies, the RTOG 0415 and the HYPRO trial
have also just been published in detail [11, 15]. The studies
from Yeoh et al. [20, 26] and Lukka et al. [12] are of lim-
ited interest, as total doses applied in each of the study arms
nowadays would be regarded as far below established stan-
dards of care. This is true for the techniques used in these
studies as well. Some of these studies did use or at least
permit hypofractionation in conjunction with simultaneous
integrated boost techniques (e. g. CHHIP and HYPRO) and
only very rarely examined the treatment of the pelvic lymph
nodes with hypofractionated external beam radiotherapy [8,
18].
Toxicity
Whereas the median follow-up might already be sufficient
to estimate outcome in terms of side effects, this is not
true for the primary endpoint of disease control where
longer follow-up is needed. Some caveats exist. In the
HYPRO study, cumulative acute gastrointestinal (GI) tox-
icity grade 2 and worse was significantly increased (42 %
vs. 31.2 %, p = 0.0015) in the hypofractionated arm, lead-
ing to the statement that hypofractionated radiotherapy was
not non-inferior in terms of acute side effects [14]. In the
gastrointestinal subitems evaluated, there was a marked dif-
ference with respect to increased stool frequency ≥6 times
a day (15 % vs. 8 %, p = 0.0035) and in pain needing drugs
(9 %vs. 5 %, p = 0.021). In genitourinary (GU) toxicity
there was no difference in general but in the subitem in-
creased frequency at night more than 7 times (grade 3)
there again was a significant increase in the hypofraction-
ation group (12 % vs. 7 %, p = 0.019). Late toxicity of the
HYPRO study has been recently reported [13]. Grade 2 or
worse GU toxicity at 3 years was increased (hazard ratio HR
1.16) from 39.0 % to 41.3 % and grade 2 or worse gastroin-
testinal toxicity at 3 years increased from 17.7 % to 21.9 %
(HR 1.19). Especially cumulative grade 3 or worse late
GU toxicity was significantly higher with an increase from
12.9 % to 19.0 % (p = 0.021). The subitems that were of
special concern were nycturia ≥6 (1 % vs. 6 %, p = 0.0005),
incontinence (14 % vs. 20 %, p = 0.04) and stool frequency
≥6 (3 % vs. 7 %, p = 0.034). Thus, the authors again had to
state that with respect to late toxicity non-inferiority could
not be shown. As there was no significant difference, nei-
ther in 5-year relapse-free survival nor in treatment failure,
the authors concluded that their hypofractionated radiother-
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apy regimen could not be regarded as the new standard of
care [15].
With regard to acute side effects the results of the CHHiP
trial pointed in the same direction as there was a statisti-
cally significant increase in acute grade 2 or more GI tox-
icity in the two hypofractionated arms of the trial (25 %
vs. 38 % p < 0.0001) [16]. The 5-year biochemical or clin-
ical failure-free survival rates were in a relatively narrow
range from 85.9 % for the 57 Gy in 19 fractions regimen
up to 90.6 % for 60 Gy in 20 fractions and the convention-
ally fractionated radiotherapy regimen lying just in between
with 88.3 %. Due to the predefined hazard ratios (HR) for
the 57 Gy regimen, non-inferiority in comparison to stan-
dard fractionation could not be claimed, whereas for the
60 Gy regimen non-inferiority was documented. At 5 years
there were no significant differences in grade 1, grade 2,
grade 3 or worse bowel, bladder or sexual symptoms.
The Fox Chase and the HYPRO studies noted an in-
creased risk for late GU toxicity in patients with impaired
urinary function prior to the commencement of radiother-
apy [15, 18, 27]. For other outcome domains of interest,
such as sexual functioning and well-being [28, 29] there
are not enough data available yet.
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Fig. 1 Major randomized trials on moderate hypofractionation in prostate cancer. Biologically effective doses (BED) are depicted and compared
for different alpha/beta values. The assumptions made in the study protocols on alpha/beta values for prostate cancer and organs at risk are shown
in vertical lines. OTT overall treatment time, IMRT intensity modulated radiotherapy, SIB simultaneous integrated boost, 3D-CRT 3-dimensional
conformal radiotherapy
In the RTOG 0415 study, no differences in early GI or
GU adverse events were observed. Late grade 2 and 3 GI
adverse events were approximately 60 % more likely in men
who were assigned to treatment with hypofractionated RT
(HR, 1.55–1.59). Similarly, late grade 2 and 3 GU adverse
events were more likely in men treated with hypofraction-
ated radiotherapy (HR, 1.31 to 1.56). No differences in
more severe events were observed [11].
Of note, both the HYPRO and RTOG studies might have
used higher biologically effective doses in their experimen-
tal (hypofractionated) arms than in the control cohorts. Both
the HYPRO and the RTOG trial were based on the assump-
tion of α/β values of 1.5 Gy for prostate cancer. In the
RTOG trial, even if assuming an α/β of 2 Gy for prostate
cancer, the experimental arm resulted in an EQD2 (equiv-
alent dose for a 2 Gy fraction) of 79 Gy vs. 70 Gy for the
standard treatment. Likewise, in the HYPRO study, the re-
spective groups were treated with an EQD2 of 87 Gy vs.
78 Gy to the prostate. Assuming an α/β value of 3.0 Gy for
late rectal reactions, the EQD2 values would have been 6 Gy
higher in the experimental arms of both trials and the ob-
served differences in toxicity rates may be also attributable
to biologically effective higher doses in the HF arms (see
Fig. 1a–d), where the different fractionation schemes of the
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most relevant phase 3 studies are compared on basis of α/β
values ranging from 1 Gy to 10 Gy.
Hypofractionation in adjuvant and salvage
treatment
Data on moderate hypofractionation in postoperative or sal-
vage radiotherapy of prostate cancer are sparse and the few
reports available are retrospective in nature. As there are
already reports on unexpected high rates of up to 28 %
grade 3 late GU toxicity [30, 31] it seems very wise to
abstain from hypofractionation in the postoperative setting
outside carefully designed clinical trials, keeping in mind
that in this situation the target volume irradiated mainly
consists of normal tissue.
Current trials in moderate hypofractionation
As already mentioned, there are several large scale trials
that have already completed accrual and published results
and hopefully in the near future more details especially sub-
group analyses will be presented. The collaborate OCOG/
TROG PROFIT Prostate Fractionated Irradiation Trial
(NCT00304759) testing 78 Gy/39 fractions in 8 weeks vs.
60 Gy/20 fractions in 4 weeks (i. e. the same regimen as
the 20 fractions schedule of the CHHiP trial) for inter-
mediate risk prostate cancer has completed its accrual of
more than 1200 men and first results were reported at the
American Society of Clinical Oncology Annual Meeting
2016 [32]. Clinicaltrials.gov. lists the Canadian trial on
Hypofractionated Dose Escalation Radiotherapy for High
Risk Adenocarcinoma of the Prostate 76 Gy/38 fractions
vs. 68 Gy/25 fractions (NCT01444820) and the closed
MD Anderson phase III study (NCT00667888), comparing
75.6 Gy/42 fractions vs. 72 Gy/30 fractions with no fur-
ther details. Some insight into the outcomes of extreme vs.
moderate hypofractionation may be derived from the HEAT
trial, comparing 70.2 Gy in 26 fractions vs. 36.25 Gy in
5 fractions (NCT01794403).
Summary on moderate hypofractionation
There is a growing body of evidence that modern moder-
ately hypofractionated regimens are safe and non-inferior
to conventional fractionation in terms of clinical and bio-
chemical recurrence-free survival and late toxicity. Special
precaution is needed for particular subgroups of patients
with a substantially higher risk of acute GI toxicity and late
GU toxicity who apparently are not eligible candidates for
hypofractionation. An important caveat in the assessment
of hypofractionation in prostate cancer remains the fact
that although supportive evidence is growing, the present
review and recommendations are limited by the fact of still
immature data; therefore, the DEGRO expert panel strongly
recommends:
1. To restrict the use of moderate hypofractionation to high-
end techniques including IGRT and IMRT in carefully
selected patients and to adhere to published phase 3 pro-
tocols with documented safety and efficacy. The CHHiP
regimen with 60 Gy in 20 fractions over 4 weeks or the
RTOG regimen with 70 Gy in 28 fractions over 6 weeks
at present seem to be the first choices, although it has to
be kept in mind that in the CHHIP trial equivalency was
shown only in comparison to 74.0 Gy in standard frac-
tionation, which might be regarded a rather low dose for
the patients treated, who predominantly had intermediate
risk disease.
2. Meticulous follow-up and documentation of outcome and
late toxicity are mandatory.
3. Hypofractionated radiotherapy of the pelvic lymphatic
vessels is experimental and should not be carried out ex-
cept in clinical trials.
4. Hypofractionated radiation therapy in postoperative and
in salvage situations is experimental and should not be
carried out except in clinical trials.
Extreme hypofractionation
Extreme hypofractionation with single doses of >4–10 Gy
up to total doses of 35–50 Gy, is most often applied
with stereotactic body radiotherapy (SBRT) techniques.
Throughout the last 5 years, a growing number of phase I/II
studies as well as retrospective analyses of extreme hy-
pofractionation schedules have been published, with me-
dian follow-up periods of roughly 6 years at maximum
[33–35]. Four to five fractions of single doses between
7 Gy and 10 Gy have been used, with estimated biologi-
cally equivalent doses of up to an EQD2 of 164 Gy [36]
applied in only 1–2 weeks; therefore, these regimens are
also frequently termed stereotactic ablative radiotherapy
(SABR). These very high doses necessitate small PTV
margins and utmost precision with respect to both inter-
fraction and intrafraction motion of the prostate. This can
be achieved with live tracking image guidance strategies
based on fiducials or on electromagnetic beacon transpon-
der technologies. In most of these reports dedicated robotic
radiosurgery units were used; alternatively, IGRT-IMRT on
specially equipped linacs was performed.
Clinical evidence
In the vast majority these studies included only low-risk
and intermediate-risk patients. For this selections early can-
K
8 Strahlenther Onkol (2017) 193:1–12
cer outcomes have been excellent, with unanimously re-
ported bNED rates of > 90 % up to 100 % in short and mid-
term follow-up. In the largest single institution study with
a 72-month median follow-up, Katz and Kang. [35] treated
515 patients to 35–36.25 Gy in 5 fractions. Low-risk pa-
tients showed a freedom from biochemical failure rate of
95.8 % at 7 years. Results for intermediate and high-risk pa-
tients were 89.3 % and 68.5 %, respectively. Loblaw et al.
[37] treated only low-risk prostate cancer patients and had
a similar follow-up of 55 months. The authors noted a 5-
year biochemical control of 98 %, also confirmed in post-
treatment biopsies in 85 % of the patients. Out of these, only
4 % were classified positive for residual cancer 3 years after
treatment. These excellent results are comparable to a high-
dose IMRT series obtained in a phase 3 trial for low-risk
disease [38].
An overview of trials comprising of at least 50 patients
and results following extreme hypofractionation is provided
in table 2 [33–35, 37, 39–51]. Additional evidence is pro-
vided by the Registry for Prostate Cancer Radiosurgery
(RPCR) with an analysis of the largest cohort so far treated
by extreme hypofractionated SBRT [43]. Between 2010
and 2013, almost 1750 men from 45 participating sites
were enrolled, with the majority (86 %) receiving SBRT
as monotherapy. At 2-year follow-up, biochemical disease-
free survival amounted to 92 %, which is in line with the
few prospective series. The data presented by Freeman et
al. [43] are to some extent limited by incomplete data entry
into the database and thus an inherent risk of underreport-
ing of outcomes that were undesired. To what extent these
registry data include patients already reported on in other
series remains another open question.
Toxicity
Moderate to high-grade acute toxicity from extreme hy-
pofractionation ranges between 10 % and 20 %, with
urinary symptoms more common than those related to
the bowels and rectum. Late grade 2 toxicity rates from
these individual institutional experiences vary significantly
(1–31 %), with grade 4 toxicity occasionally reported [36,
37, 49]. While urinary incontinence is uncommon in con-
ventional fractionation, in one study it was reported to be
as high as 10 % in previously continent men 3 years post-
SBRT [52]. Many of the toxicity rates published are crude
rates, not taking into account patients lost to follow-up and
thus actuarial rates may be in fact higher than reported [4].
Earlier studies have noted particularly high urinary toxicity
rates, with late grade 2 rates of up to 30–40 % [50, 53, 54],
pointing at the necessity of high quality levels in perform-
ing marker-based, image-guided SBRT. The hypothesis
of an α/β ratio for urethra and bladder that is lower than
commonly assumed builds a caveat towards unexpectedly
increased late toxicity. In a large retrospective case control
study of Medicare claims, 1335 extreme HF-SBRT patients
were matched to 2670 CF-IMRT patients and 2 years post-
treatment, higher late GU toxicity events were noted in the
hypofractionated group (43.9 % vs 36.3 %; p = 0.001) [53].
The increase in GU toxicity was due to claims indicative of
urethritis, urinary incontinence and/or obstruction. Treat-
ment on non-consecutive days may reduce late toxicity.
One study found lower rates of grade 1–2 urinary (17 %
vs 56 %; p = 0.007) and rectal (5 % vs 44 %; p = 0.001)
toxicity with a regimen of every other day versus daily
dosing [33].
A comprehensive overview of the late GI/GU toxicity
rates as a function of prescription dose is provided by
Koontz et al. comprising the majority of extreme HF study
results published at that time [4]. Several of the studies have
reported grade 4 GI toxicities (i.e. colostomy) at high total
doses. In 1 study patients were treated with 5 fractions of
7 Gy and 2 studies used 9–10 Gy per fraction. An update
of a dose-escalation study performed by Boike et al. [36]
noted a 2-year actuarial rate of 8 % high-grade GI toxicity
in 61 patients receiving 50 Gy in 5 fractions [55] and 5
patients required a diverting colostomy at a median time
of 9.5 months. The volume of rectum receiving 50 Gy was
highly significant on multivariate analysis. Katz et al. [35]
noted decreased grade 2 GU toxicity in patients receiv-
ing 35 Gy rather than 36.25 Gy in 5 fractions (5.7 % vs
10.6 %) and overall grade 2 or higher toxicity was signifi-
cantly higher after 36.25 Gy (p = 0.05). Another study noted
increased high-grade rectal toxicity with increasing dose,
recommending <50 % of the rectal volume receiving 4.8 Gy
per fraction [55]. In a series of 204 patients reported by
Rana et al., HF-SBRT with 35–36.25 Gy resulted in an acute
increase in irritative urinary symptoms that peaked within
the first month posttreatment. Irritative voiding symptoms
returned to baseline in the majority of patients by 3 months
post-SBRT and were actually improved from baseline at
3 years post-SBRT [56]. In the RPCR cohort, no grade 3
late urinary toxicity was reported. One patient developed
grade 3 gastrointestinal toxicity (rectal bleeding). Erectile
function was preserved in 80 % of men <70 years old [43].
Current trials of extreme hypofractionation
Currently, three phase 3 trials of extreme hypofractiona-
tion are active [4]: the Scandinavian Hypofractionated Ra-
diotherapy of Intermediate Risk Localized Prostate Cancer
trial (HYPO-RT-PC; ISRCTN45905321) randomizes inter-
mediate-risk men to 42.7 Gy in 7 fractions versus 78 Gy
in 39 fractions. The Prostate Advances in Comparative Ev-
idence (PACE) trial, active in multiple European centers,
will randomize 1036 men to (1) robotic surgery or prostate
SBRT or (2) moderate versus extreme hypofractionation
K
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Table 2 Major prospective studies on extreme hypofractionated external beam radiotherapy for prostate cancer
n Median
FU
(months)
Risk group Techniques Regimen
(TD/fx)
Outcome Toxicity
Aluwini [39] 162 28 Low/
intermediate
n. s. 38 Gy/4 fx BC 98 % @ 3 years G 2 GU 15 %
G 2 GI 3 %
Bolzicco [40] 100 36 41 % low
42 % intermedi-
ate
17 % high
Robotic
IGRT
35 Gy/5 fx
29 % ADT
BC 96 % G 1/2/3 GU
4 %/3 %/1 %
G 1/2/3 GI
2 %/1 %
Chen et al. [41] 100 28 37 % low
55 % intermedi-
ate
8 % high
Robotic
IGRT
35–36.25
Gy/5 fx
11 % ADT
BRFS 99 % @ 2 years 2 y G ≥ 2 GU
31 %
2 y G ≥ 2 GI 1 %
D’Alimonte et al.
[42]
84 50 100 % low IMRT/
IGRT
35 Gy/5 fx BC 98 % G 2/≥3 GU 5/1 %
G 2/≥3 GI 5/1 %
Friedland
et al.[34]
122 24 72 % low
28 % intermedi-
ate +
high
Robotic
IGRT
35 Gy/5 fx -
36.3 Gy/5 fx
19 % ADT
FFBF 97 % G 3+ GU 0 %
G 3+ GI 1 %
Freeman (2015)
(RPCR registry)
1743 n. s. 41 % low
42 % intermedi-
ate
10 % high
7 % data missing
Mainly
robotic
IGRT
35–40 Gy/
4–5 fx
(8 %
SBRT-boost
19.5–21.8 Gy/
3 fx after
45–50 Gy
EBRT)
FFBF 92 % @ 2 years
99 % low risk
97–85 % interm.
87 % high
G3 GU 0 %
G3 GI 0 %
Fuller et al. [44] 260 20 45 % low
55 % intermedi-
ate
n. s. 38 Gy/4 fx BRFS 98 % @ 3 years G 3 GU 2 %
(any G 44 %)
G 3 GI 0 %
(any G 11 %)
Katz and Kang
[35]
515 72 63 % low
30 % intermedi-
ate
7 % high
Robotic
IGRT
35–36.25
Gy/5 fx
FFBF @ 7 years
96 % (low risk)
89 % (interm.r.)
69 % (high risk)
G ≥ 2 GU 9 %
G ≥ 2 GI 4 %
King et al. [33] 67 32 100 % low Robotic
IGRT
36.25 Gy/5 fx 92 % G ≥ 2 GU 7 %
G ≥ 2 GI 12 %
Loblaw et al. [37] 84 55 100 % low IMRT/
IGRT
35 Gy/5 fx 70 % 5 y G ≥ 2 GU 5 %
5 y G ≥ 2 GI 7 %
Lukka et al. [45] 240 n. s. Low IMRT/
IGRT
36.3 Gy/5 fx
51.6 Gy/12 fx
n. s. Changes in EPIC
bowel & urinary
domain scores:
both regimens
well tolerated
Mantz et al. [46] 91 24 Low and inter-
mediate
IMRT/
IGRT
36.3 Gy/5 fx
22.0 Gy/4 fx
FFBF 97 % G 3+ GU 5 %
G 3+ GI 1 % (G 4)
Meier et al. [47,
48]
129 30 100 % intermedi-
ate
Robotic
IGRT
40 Gy/5 fx
No ADT
BRFS 94 % @ 4 years G 2 GU 10 %
G 2 GI 2 %
Menkarios et al.
[49]
80 33 100 % low IMRT/
IGRT
45 Gy/5 fx BC 98 % @ 5 years G ≥ 2 GU 14 %
G ≥ 2 GI 16 %
Oliai et al. [50] 70 37 51 % low
31 % intermedi-
ate
17 % high
Robotic
IGRT
35 Gy/5 fx
36.3 Gy/5 fx
37.5 Gy/5 fx
33 % ADT
FFBF
100 %/95 %/77 %
G 3+ GU 3 %
G 3+ GI 0 %
Quon et al. [51] 84 18 100 % low IMRT/
IGRT
35 Gy/5 fx BRFS 99 % @ 3y G 2 GU 2 %
G 2 GI 5 %
ADT androgen deprivation therapy, BC biochemical control, BRFS biochemical relapse-free survival, FFBF freedom from biochemical failure,
FU follow-up, T total dose, fx number of fractions, GI gastrointestinal, G grade, GU genitourinary, IGRT image-guided radiation therapy, IMRT in-
tensity-modulated radiation therapy, n. s. not stated, EBRT external beam radiotherapy in standard fractionation.
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with 5-year biochemical progression-free survival as the
primary end point (NCT01584258). A similar approach
is tested by the RTOG in a phase II randomized multi-
center trial to assess quality of life outcomes, acute and
late toxicity of two different extreme hypofractionated reg-
imens: 36.25 Gy in 5 fractions of 7.25 Gy twice a week
and 51.6 Gy in 12 daily fractions of 4.3 Gy (RTOG 0938,
NCT01434290). Finally, the Proton Cooperative Group is
randomizing 192 patients in a phase 3 study of 79.2 Gy in
44 fractions or 38 Gy in 5 fractions, using a primary end
point of 5-year freedom from failure (NCT01230866). All
these studies are still recruiting, and results are pending.
Summary
In selected non-randomized cohorts, clinical outcome fol-
lowing extreme hypofractionation regimens for low-risk
prostate cancer shows good short and mid-term biochem-
ical control up to 5 years, well comparable with current
conventional high-dose fractionation. The American Soci-
ety for Radiation Oncology recently released their policy on
SBRT stating that while longer outcome is still necessary, it
is regarded suitable to offer SBRT to selected low and inter-
mediate-risk prostate cancer patients; however, in the light
of the reports of higher grade urinary and rectal toxicity and
in the absence of long-term experience derived from ran-
domized controlled trials, the DEGRO expert panel strongly
discourages its use outside prospective clinical protocols.
Hypofractionated radiotherapy with protons and
ions
Prerequisites
Particle therapy of prostate cancer is currently not routine
procedure. As there are potential benefits due to the phys-
ical differences in dose distribution compared to photon
therapy, there is an increasing interest. Physically, it is pos-
sible to focus the particles in the tumor while minimizing
the dose to the surrounding healthy tissue; therefore, the
beneficial dose distribution might reduce the risks of long-
term toxicity (assuming similar fractionation and dose con-
cepts). Also, a reduction of radiation-associated secondary
cancers is postulated due to the reduced dose in surrounding
tissues; however, in clinical routine the same requirements
are necessary as for photon therapy: in particular, a daily
verification of target volumes immediately before irradia-
tion (image guided proton therapy, IGPT) is essential. As
the range of protons is very sensitive to the density of irradi-
ated tissue, the set-up alignment focuses on bony structures
in the beam; therefore, in contrast to photon therapy, the
interfractional movement of the prostate cannot be easily
corrected. This can only be compensated partly by careful
preparation of the patient (e. g. rectal balloon, fiducials).
From the radiobiological point of view, there might be
(after application of correction factors) probably little dif-
ference between radiotherapy for prostate cancer with pro-
tons or photons. In the hypofractionated setting this might
be an issue, especially in Germany with respect to approval
and regulations [57].
Clinical data
The information on carbon ion therapy for prostate cancer
is very limited. Many of the reports originate from cen-
ters with much experience in particle therapy, mainly from
Japan but are retrospective in nature and only very few
cover a number of patients that will allow valid conclusions
to be drawn [58, 59]. Prospective studies are usually of even
smaller size [60]. Data on proton therapy are more robust,
and proton therapy in standard fractionation is in routine
use in many centers for definitive treatment of prostate can-
cer and detailed information is available [38, 61]. In a small
phase 3 study, Vargas et al. [62] compared standard frac-
tionated proton therapy with 79.2 GyE in 44 treatments
with an extremely hypofractionated schedule of 38 GyE
in 5 fractions. There were no major differences at an in-
terim analysis although the American Urological Associa-
tion Symptom Index at 12 months did show a significant
deterioration (p = 0.04) in the hypofractionated arm. A me-
dian follow-up of only 18 months and a total number of
patients of 82 limit the possibility of further interpretation.
Finally, the Heidelberg University ion facility recently fin-
ished a pilot study to compare hypofractionated therapy
with carbon ions to protons [63].
In summary, the DEGRO expert panel recommends that
hypofractionation with heavy ions should not be used out-
side clinical trials.
In absence of long-term experience derived from ran-
domized controlled trials, the DEGRO expert panel rec-
ommends the use of hypofractionated proton therapy in
prostate cancer in prospective clinical protocols.
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